A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome

Roger Kurlan, Giovanna Crespi, Barbara Coffey, Kirsten Mueller-Vahl, Stephen Koval, Glen Wunderlich, Kirsten Mueller-Vahl, Andrea Ludolph, Johathan Liss, Barbara Coffey, Donald Lewis, Michael Bengtson, Jose Zaglul, Willis Holloway, Judith Owens, Cathy Budman, Joseph Jankovic, Moira Rynn, Daniel Geller, Katie KompolitiMark LeDoux

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome. Methods: There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome. Results: There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole -7.16) and placebo -7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo. Conclusions: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder.

Original languageEnglish (US)
Pages (from-to)775-778
Number of pages4
JournalMovement Disorders
Volume27
Issue number6
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • Dopamine agonist
  • Pramipexole
  • Tics
  • Tourette's syndrome
  • Treatment, clinical trial

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome'. Together they form a unique fingerprint.

Cite this